Biological Aspects of High LET Radiation Therapy

Radiology ◽  
1977 ◽  
Vol 125 (2) ◽  
pp. 493-496 ◽  
Author(s):  
Paul Todd
2015 ◽  
Vol 1084 ◽  
pp. 559-566
Author(s):  
Jacobus Slabbert ◽  
Anne Vral

When a cancer type proves to be radioresistant to treatment with X-rays, the use of neutrons may constitute therapeutic gain provided the cells are relatively sensitive to high-LET radiation. In this work studies with different tumor cell types are reported following exposure to either photons or different neutron energies used in clinical radiation therapy. Potential for therapeutic gain is clearly noted for neutrons with a mean energy of 6 MeV whilst that for 29 MeV neutrons is dependent on the cell types used in the study.


CHEST Journal ◽  
1989 ◽  
Vol 96 (1) ◽  
pp. 72S-73
Author(s):  
M. Austin-Seymour ◽  
T. Griffin ◽  
G. Laramore ◽  
M. Maor ◽  
R. Parker

CHEST Journal ◽  
1989 ◽  
Vol 96 (1) ◽  
pp. 72S-73S ◽  
Author(s):  
M. Austin-Seymour ◽  
T. Griffin ◽  
G. Laramore ◽  
M. Maor ◽  
R. Parker

2020 ◽  
Vol 21 (21) ◽  
pp. 8151
Author(s):  
Sharda Kumari ◽  
Shibani Mukherjee ◽  
Debapriya Sinha ◽  
Salim Abdisalaam ◽  
Sunil Krishnan ◽  
...  

Radiation therapy (RT), an integral component of curative treatment for many malignancies, can be administered via an increasing array of techniques. In this review, we summarize the properties and application of different types of RT, specifically, conventional therapy with x-rays, stereotactic body RT, and proton and carbon particle therapies. We highlight how low-linear energy transfer (LET) radiation induces simple DNA lesions that are efficiently repaired by cells, whereas high-LET radiation causes complex DNA lesions that are difficult to repair and that ultimately enhance cancer cell killing. Additionally, we discuss the immunogenicity of radiation-induced tumor death, elucidate the molecular mechanisms by which radiation mounts innate and adaptive immune responses and explore strategies by which we can increase the efficacy of these mechanisms. Understanding the mechanisms by which RT modulates immune signaling and the key players involved in modulating the RT-mediated immune response will help to improve therapeutic efficacy and to identify novel immunomodulatory drugs that will benefit cancer patients undergoing targeted RT.


1989 ◽  
Vol 117 (2) ◽  
pp. 351 ◽  
Author(s):  
Robert W. Atcher ◽  
Angelo Russo ◽  
William G. DeGraff ◽  
Mark Moore ◽  
David J. Grdina ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document